Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics
Biomolecules · 2026
DOI: 10.3390/biom16091268 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Moon-Soo Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innovative Drug Discovery and Development, College of Pharmacy, Keimyung University, 10, Daegu 42601, Republic of Korea. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korean government.
Abstract (Originalsprache)
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) system began as a tool for programmable genome editing. CRISPR/Cas technologies have evolved into a versatile platform for functional genomic screening, epigenome editing, therapeutic target discovery, and highly sensitive molecular diagnostics. New effectors and engineered variants continue to push these applications into personalized medicine and point-of-care testing. Here, this review highlights recent advances in therapeutic target discovery and therapeutic and molecular diagnostic development utilizing CRISPR/Cas technologies. We discuss how CRISPR interference (CRISPRi), CRISPR activation (CRISPRa), base editing, and prime editing have improved our understanding of disease mechanisms, while creating new opportunities for therapeutic intervention. Current applications in cancer immunotherapy, infectious disease, and neurological disorders are also discussed. In diagnostics, CRISPR-based platforms enable sensitive detection of infectious pathogens, cancer biomarkers, and genetic disorders using programmable nuclease activity in both laboratory and point-of-care settings. Collectively, these advances continue to expand the role of CRISPR/Cas technology across biological discovery, disease diagnostics, and therapeutic development, driving progress in precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Innovative Drug Discovery and Development, College of Pharmacy, Keimyung University, 10, Daegu 42601, Republic of Korea.
ORCID-Profile: Moon-Soo Kim
Förderung
- National Research Foundation of Korea
- Korean government
Zitieren
APA
Kim, M. S., Do, H. S., Jang, H. Y., Lee, K. E., & Lee, S. J. (2026). Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics. Biomolecules. https://doi.org/10.3390/biom16091268
Vancouver
Kim MS, Do HS, Jang HY, Lee KE, Lee SJ. Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics. Biomolecules. 2026. doi:10.3390/biom16091268
BibTeX
@article{Kim2026,
author = {Kim, Moon-Soo and Do, Hae Sol and Jang, Hye Yeon and Lee, Kang Eun and Lee, Sun Ju},
title = {Recent Advances in CRISPR/Cas Technologies for Biological Discovery, Therapeutics, and Diagnostics},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16091268}
}
EUVIMED